Robert Peters PhD

Robert Peters is a Chief Scientific Officer at the Ensoma. Rob holds a Bachelor of Science in biological engineering from Cornell University and a Doctor of Philosophy in biochemistry from the laboratory of Tom Maniatis, Ph.D., at Harvard University.

Rob Peters brings to Ensoma more than 20 years of research and development experience, including working on recombinant clotting Factor VIll and Factor IX Fc fusion proteins from their inception in research through manufacturing, clinical development, and supporting market launch as Eloctate/Elocta and Alprolix, the first extended half-life clotting factors for the treatment of hemophilia A and B, respectively.

Prior to Ensoma, Rob was a rare blood disorders head, of research at Sanofi, where he helped establish the therapeutic area following the acquisition of Bioverativ, Ablynx, and full control of fitusiran from Alnylam. There, he helped advance BIVv001, a further engineered FVIl fusion protein that began within his research group at Biogen, into Phase 3 clinical trials. Previously, Rob led the establishment of the research area in the Biogen spinoff Bioverativ as senior vice president, research, where he advanced a number of programs from research to clinical development and integrated a number of complement R and D programs brought in by the company's acquisition of True North Therapeutics.

Rob began his career as the 11 employees at the VC-backed startup Syntonix, where the promising preclinical data on the rFVIIFc and rFIXFc fusion proteins led to the company's acquisition by Biogen. There, he ultimately became vice president, of hematology research, and oversaw the expansion of the portfolio beyond biologics to include small molecules, in vivo liver-directed lentiviral gene replacement, and ex vivo HSC gene-editing programs in conjunction with academic and industry partners in hemophilia and sickle cell disease.